Drug intelligence / Profile preview

Navosac

Development stage: Unknown
Lead developer: BioDiem
Modality: Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

Navosac is a Live Attenuated Influenza Vaccine (LAIV) that was launched in India by the Serum Institute of India (SII). The technology for this vaccine was licensed from BioDiem. As an LAIV, it works by introducing a weakened form of the influenza virus to stimulate the immune system, thereby providing protection against influenza.

Brand names: Navosac

Targets

Flu (Influenza surface proteins)

Beyond the preview

Go deeper on Navosac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Navosac.

Explore the full profile